Role of healthcare providers expands in dcts
Even before the COVID pandemic, most clinical trials already had decentralized components such as blood draws completed at locations other than the designated trial site. However, the pandemic created an opportunity for a new decentralized component, telemedicine, with remote visits. Inexpensive telecommunication platforms, immensely popular in ordinary life, became very successful in routine healthcare, as evidenced by the massive increase in telemedicine claims during the pandemic. Telehealth claim lines increased 2980% in the US from September 2019 to September 2020, according to FAIR Health’s Monthly Telehealth Regional Tracker.
In this article, we highlight a technological advance in portable imaging that could further increase the scope of DCTs, but is it really feasible to keep adding technical responsibilities to the role of mobile/local healthcare providers working in a decentralized trial environment?
Chief Medical Officer and Co-founder
Pharma industry veteran with 30+ years in large Pharma & in leading small biotechs, spearheading large initiatives and securing funding, psychiatry practice and research for 10+ years.